Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782332 | 1.00 | ANPEP (0.57) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL5658127 | 1.00 | ANPEP (0.57) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL8069933 | 1.00 | ANPEP (0.57) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL27487680 | 0.89 | ANPEP (0.53) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL7284516 | 0.89 | ANPEP (0.53) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL10448479 | 0.89 | ANPEP (0.53) | ANPEPALDH1A1MEN1KMT2ASIGMAR1 | |
| Hydrochloric Acid SCHEMBL8617719 | 0.87 | ANPEP (0.52) | ANPEPMEN1KMT2ASIGMAR1 | |
| SCHEMBL4170192 | 0.87 | TRPM8 (0.55) | ANPEPALDH1A1MEN1KMT2AATM | |
| SCHEMBL4166663 | 0.87 | TRPM8 (0.55) | ANPEPALDH1A1MEN1KMT2AATM | |
| Hydrochloric Acid SCHEMBL27488757 | 0.87 | ANPEP (0.52) | ANPEPMEN1KMT2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2024-03-05 | — | — | US | disclosed |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2023-05-30 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2023-01-05 | — | — | US | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| EP-3607996-B1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PF MEDICAMENT (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2022-04-07 | — | — | US | disclosed |
| EP-3388427-B1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PF MEDICAMENT (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312343-B2 | N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 | HOFFMANN-LA ROCHE INC. (US) | 2007-12-25 | — | — | US | disclosed |
| CN-1960965-A | Synthesis of amino-alkoxy-heptanoic alkyl ester | HOFFMANN LA ROCHE (CH) | 2007-05-09 | — | — | CN | disclosed |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-08 | — | — | US | disclosed |
| EP-0853612-B1 | ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME | CENTRE NAT RECH SCIENT (FR) | 2000-06-14 | — | — | EP | disclosed |
| US-5962722-A | α-hydrazino acid derivatives and method for making same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1999-10-05 | — | — | US | disclosed |
| EP-0853612-A1 | ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1998-07-22 | — | — | EP | disclosed |
| WO-1997009303-A1 | ALPHA-HYDRAZINO ACID DERIVATIVES AND METHOD FOR MAKING SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1997-03-13 | — | — | WO | disclosed |
| WO-1997005126-A1 | MUPIROCINSULFAMATES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ANPEP 453/4885ALDH1A1 1223/4885MEN1 1759/4885 |
| US-20230002316-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | NR1H4, HCAR3, VDR | ANPEP 2321/4885ALDH1A1 2916/4885MEN1 2933/4885 |
| US-11918656-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | ANPEP 453/4885ALDH1A1 1223/4885MEN1 1759/4885 |
| US-11661457-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | ANPEP 1363/4885ALDH1A1 839/4885MEN1 285/4885 |
| US-20050272665-A1 | Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters | ALDH7A1, BCAT1, BCAT2 | ANPEP 40/4885ALDH1A1 88/4885MEN1 1424/4885 |
| US-20220105195-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | ANPEP 657/4885ALDH1A1 982/4885MEN1 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.